stockportfolio.pro
Stocks / BAX vs NUVL
BAX vs NUVL
Baxter International Inc. and Nuvalent, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
BAX is the larger company ($10.0B vs $9.8B). On the fundamentals, BAX has the stronger return on equity (-15.6% vs -34.1%). Full numbers below — the stronger figure on each row is in green.
| Baxter International Inc. (BAX) | Nuvalent, Inc. (NUVL) | |
|---|---|---|
| Market cap | $10.0B | $9.8B |
| Revenue (latest FY) | $11.24B | $0 |
| Net income (latest FY) | $-957.00M | $-425.38M |
| Revenue growth (5y CAGR) | -0.7% | — |
| Net margin | -8.5% | — |
| Return on equity | -15.6% | -34.1% |
| P/E ratio | — | — |
| Dividend yield | 1.0% | — |
| Profitable years (of last 10) | 7 | 0 |
| Positive free cash flow | Yes | — |
Compare with another company:
See the full BAX vs NUVL breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open BAX's full financials → Open NUVL's full financials →More comparisons
Frequently asked questions
Which is bigger, BAX or NUVL?
Baxter International Inc. is larger by market capitalization — $10.0B versus $9.8B.
Which grows faster, BAX or NUVL?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.